Tetanus toxoid provides efficient T-cell help for the induction of HA-1H cytotoxic T cells

Transfusion

Volumn 46, Issue 7, 2006, Pages 1210-1220

  Eiz Vesper, Britta ^a   Horn, Peter A ^a   Daubert, Claudia ^a   Khattab, Barbara ^a   Blasczyk, Rainer ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD45RA ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN; MINOR HISTOCOMPATIBILITY ANTIGEN; MONOCLONAL ANTIBODY CD28; MONOCLONAL ANTIBODY CD3; TETANUS TOXOID;

ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN PRESENTING CELL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IMMUNOTHERAPY; PERIPHERAL BLOOD MONONUCLEAR CELL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANTIGEN PRESENTATION; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MINOR HISTOCOMPATIBILITY ANTIGENS; OLIGOPEPTIDES; T-LYMPHOCYTES, CYTOTOXIC; TETANUS TOXOID;

EID: 33746496186     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2006.00872.x     Document Type: Article

References (61)

1. Goulmy E, Schipper R, Pool J, et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996;334:281-5.
2. Wallny HJ, Rammensee HG. Identification of classical minor histocompatibility antigen as cell-derived peptide. Nature 1990;343:275-8.
3. Perreault C, Decary F, Brochu S, et al. Minor histocompatibility antigens. Blood 1990;76:1269-80.
4. de Bueger M, Bakker A, Van Rood JJ, et al. Tissue distribution of human minor histocompatibility antigens: ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J Immunol 1992;149:1788-94.
5. Barrett AJ. Mechanisms of the graft-versus-leukemia reaction. Stem Cells 1997;15:248-58.
6. Falkenburg JH, Marijt WA, Heemskerk MH, Willemze R. Minor histocompatibility antigens as targets of graft-versus-leukemia reactions. Curr Opin Hematol 2002;9:497-502.
7. Falkenburg JH, Willemze R. Minor histocompatibility antigens as targets of cellular immunotherapy in leukaemia. Best Pract Res Clin Haematol 2004;17:415-25.
8. Goulmy E. Minor histocompatibility antigens: allo target molecules for tumor-specific immunotherapy. Cancer J 2004;10:1-7.
9. Mutis T, Ghoreschi K, Schrama E, et al. Efficient induction of minor histocompatibility antigen HA-1-specific cytotoxic T-cells using dendritic cells retrovirally transduced with HA-1-coding cDNA. Biol Blood Marrow Transplant 2002;8:412-9.
10. Dickinson AM, Wang XN, Sviland L, et al. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med 2002;8:410-4.
11. Mutis T, Gillespie G, Schrama E, et al. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Nat Med 1999;5:839-42.
12. Spierings E, Wieles B, Goulmy E. Minor histocompatibility antigens - big in tumour therapy. Trends Immunol 2004; 25:56-60.
13. Nagase T, Seki N, Ishikawa K, et al. Prediction of the coding sequences of unidentified human genes. VI. The coding sequences of 80 new genes (KIAA0201-KIAA0280) deduced by analysis of cDNA clones from cell line KG-1 and brain. DNA Res 1996;3:321-9, 341-54.
14. den Haan JM, Meadows LM, Wang W, et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science 1998;279: 1054-7.
15. Tseng LH, Lin MT, Hansen JA, et al. Correlation between disparity for the minor histocompatibility antigen HA-1 and the development of acute graft-versus-host disease after allogeneic marrow transplantation. Blood 1999;94:2911-4.
16. Gallardo D, Arostegui JI, Balas A, et al. Disparity for the minor histocompatibility antigen HA-1 is associated with an increased risk of acute graft-versus-host disease (GvHD) but it does not affect chronic GvHD incidence, disease-free survival or overall survival after allogeneic human leucocyte antigen-identical sibling donor transplantation. Br J Haematol 2001;114:931-6.
17. Nesci S, Buffi O, Iliescu A, et al. Recipient mHag-HA1 disparity and aGVHD in thalassemic-transplanted patients. Bone Marrow Transplant 2003;31:575-8.
18. Celis E, Tsai V, Crimi C, et al. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci U S A 1994;91 (6):2105-9.
19. Romani N, Reider D, Heuer M, et al. Generation of mature dendritic cells from human blood: an improved method with special regard to clinical applicability. J Immunol Methods 1996;196:137-51.
20. Lutz MB, Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol 2002;23:445-9.
21. Oelke M, Maus MV, Didiano D, et al. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat Med 2003;9: 619-24.
22. Walter S, Herrgen L, Schoor O, et al. Cutting edge: predetermined avidity of human CD8 T cells expanded on calibrated MHC/anti-CD28-coated microspheres. J Immunol 2003;171:4974-8.
23. Schilbach K, Kerst G, Walter S, et al. Cytotoxic minor histocompatibility antigen HA-1-specific CD8+ effector memory T cells: artificial APCs pave the way for clinical application by potent primary in vitro induction. Blood 2005;106:144-9.
24. Oosten LE, Blokland E, van Halteren AG, et al. Artificial antigen-presenting constructs efficiently stimulate minor histocompatibility antigen-specific cytotoxic T lymphocytes. Blood 2004;104:224-6.
25. Bennett SR, Carbone FR, Karamalis F, et al. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+T cell help. J Exp Med 1997;186:65-70.
26. Schoenberger SP, Toes RE, van der Voort EI, et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998;393:480-3.
27. Husmann LA, Bevan MJ. Cooperation between helper T cells and cytotoxic T lymphocyte precursors. Ann N Y Acad Sci 1988;532:158-69.
28. Demotz S, Matricardi PM, Irle C, et al. Processing of tetanus toxin by human antigen-presenting cells: evidence for donor and epitope-specific processing pathways. J Immunol 1989;143:3881-6.
29. Parronchi P, Manetti R, Simonelli C, et al. Cytokine production by allergen (Der pI)-specific CD4+ T cell clones derived from a patient with severe atopic disease. Int J Clin Lab Res 1991;21:186-9.
30. York IA, Goldberg AL, Mo XY, Rock KL. Proteolysis and class I major histocompatibility complex antigen presentation. Immunol Rev 1999;172:49-66.
31. Cerny A, Fowler P, Brothers MA, et al. Induction in vitro of a primary human antiviral cytotoxic T cell response. Eur J Immunol 1995;25:627-30.
32. Ostankovitch M, Le Gal FA, Connan F, et al. Generation of Melan-A/MART-1-specific CD8+ cytotoxic T lymphocytes from human naive precursors: helper effect requirement for efficient primary cytotoxic T lymphocyte induction in vitro. Int J Cancer 1997;72:987-94.
33. Schuerwegh AJ, Stevens WJ, Bridts CH, De Clerck LS. Evaluation of monensin and brefeldin A for flow cytometric determination of interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha in monocytes. Cytometry 2001;46:172-6.
34. Verdijk RM, Kloosterman A, Pool J, et al. Pregnancy induces minor histocompatibility antigen-specific cytotoxic T cells: implications for stem cell transplantation and immunotherapy. Blood 2004;103:1961-4.
35. Mommaas B, Stegehuis-Kamp JA, van Halteren AG, et al. Cord blood comprises antigen-experienced T cells specific for maternal minor histocompatibility antigen HA-1. Blood 2005;105:1823-7.
36. Mattis AE, Bernhardt G, Lipp M, Forster R. Analyzing cytotoxic T lymphocyte activity: a simple and reliable flow cytometry-based assay. J Immunol Methods 1997;204:135-42.
37. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333:1038-44.
38. Einsele H. Immunotherapy for CMV infection. Cytotherapy 2002;4:435-6.
39. Brodie SJ, Patterson BK, Lewinsohn DA, et al. HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death. J Clin Invest 2000;105:1407-17.
40. Heslop HE, Brenner MK, Rooney CM. Donor T cells to treat EBV-associated lymphoma. N Engl J Med 1994;331:679-80.
41. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998;92:1549-55.
42. Williams CB, Engle DL, Kersh GJ, et al. A kinetic threshold between negative and positive selection based on the longevity of the T cell receptor-ligand complex. J Exp Med 1999;189:1531-44.
43. Warren EH, Greenberg PD, Riddell SR. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood 1998;91:2197-207.
44. Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 2002;99:16168-73.
45. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-4.
46. Porter DL, June CH. T-cell reconstitution and expansion after hematopoietic stem cell transplantation: "T" It Up! Bone Marrow Transplant 2005;35:935-42.
47. Bakker AB, Marland G, de Boer AJ, et al. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res 1995;55:5330-4.
48. Stuhler G, Schlossman SF. Antigen organization regulates cluster formation and induction of cytotoxic T lymphocytes by helper T cell subsets. Proc Natl Acad Sci U S A 1997;94: 622-7.
49. Mayer S, Laumer M, Mackensen A, et al. Analysis of the immune response against tetanus toxoid: enumeration of specific T helper cells by the Elispot assay. Immunobiology 2002;205:282-9.
50. Ossendorp F, Toes RE, Offringa R, et al. Importance of CD4(+) T helper cell responses in tumor immunity. Immunol Lett 2000;74:75-9.
51. James E, Chai JG, Dewchand H, et al. Multiparity induces priming to male-specific minor histocompatibility antigen, HY, in mice and humans. Blood 2003;102:388-93.
52. Oelke M, Moehrle U, Chen JL, et al. Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy. Clin Cancer Res 2000;6:1997-2005.
53. Dunbar PR, Chen JL, Chao D, et al. Cutting edge: rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma. J Immunol 1999;162:6959-62.
54. Riddell SR, Greenberg PD. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Meth 1990;128:189-201.
55. Akatsuka Y, Kondo E, Taji H, et al. Targeted cloning of cytotoxic T cells specific for minor histocompatibility antigens restricted by HLA class I molecules of interest. Transplantation 2002;74:1773-80.
56. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004;22:745-63.
57. Sallusto F, Lenig D, Forster R, et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999;401:708-12.
58. Geginat J, Lanzavecchia A, Sallusto F. Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. Blood 2003;101:4260-6.
59. Hamann D, Baars PA, Rep MH, et al. Phenotypic and functional separation of memory and effector human CD8+ T cells. J Exp Med 1997;186:1407-18.
60. Levine BL, Cotte J, Small CC, et al. Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3/CD28 costimulation. J Hematother 1998;7:437-48.
61. Krueger C, Schneck JP, Oelke M. Quality and quantity: new strategies to improve immunotherapy of cancer. Trends Mol Med 2004;10:205-8.